Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 7, 2026

Macrogenics Inc (MGNX)

A forensic read on Macrogenics Inc built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

F · Poor — capital at risk

Forensic grade

Distress

Financial health

-11.8

Distress distance

Watch

Earnings quality

Forensic signals

-3.6

P / E (ttm)

-134.2%

ROE

$256M

Market cap

0.00%

Dividend yield

-0.3%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Macrogenics Inc earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads -11.8, placing it in the Distress zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.

What the filings flag

-36.8%

FY2025

Return on invested capital. Return on invested capital is -36.8% in the latest fiscal year and rising from -78% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.

-$227.6M

FY2023–FY2025

Cash burn vs. reported loss. Over FY2023–FY2025, the company reported a cumulative net loss of $150.6M against operating cash flow of -$227.6M. Cash burn ran heavier than the reported loss — something outside net income (working capital, a cash item not in the P&L) is consuming cash faster than the loss alone implies.

+0.9%/yr

FY2022–FY2025

Share count. Diluted share count changed +3% over the last 3 years to FY2025 (+0.9%/yr). Roughly flat — the count is neither shrinking nor growing meaningfully. Per-share value isn't being meaningfully helped or hurt by the count.

Key fundamentals

Latest Revenue$149.5M

Revenue Growth YoY-0.3%

Revenue CAGR (3yr)-0.5%

Net Margin-49.9%

Free Cash Flow-$83.0M

Return on Equity-134.2%

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Macrogenics Inc's actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Aug 7, 2026. Forensic signals flag probability, not certainty.